AR102361A1 - Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 - Google Patents
Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2Info
- Publication number
- AR102361A1 AR102361A1 ARP150103381A ARP150103381A AR102361A1 AR 102361 A1 AR102361 A1 AR 102361A1 AR P150103381 A ARP150103381 A AR P150103381A AR P150103381 A ARP150103381 A AR P150103381A AR 102361 A1 AR102361 A1 AR 102361A1
- Authority
- AR
- Argentina
- Prior art keywords
- synthesa
- inhibit
- methyl
- compounds useful
- quinoline compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente solicitud se refiere a compuestos, sales de los mismos farmacéuticamente aceptables, métodos para preparar los compuestos y uso de los compuestos para tratar dolor y/o inflamación. Reivindicación 1: Un compuesto de fórmula (1) caracterizado porque: n es 1 ó 2; A se selecciona a partir de: -CH₂-, -NH-, y -O-; E es CHOCH₂- o N; X es N o CH; R se selecciona a partir de: H, -CH₃, F, y Cl; y cada R¹ es independientemente H o CH₃; G se selecciona a partir de los compuestos del grupo de fórmulas (2); siempre que cuando A es -NH- o -O-, X es CH; o una sal del mismo farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462072140P | 2014-10-29 | 2014-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102361A1 true AR102361A1 (es) | 2017-02-22 |
Family
ID=54365459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103381A AR102361A1 (es) | 2014-10-29 | 2015-10-19 | Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9969714B2 (es) |
| EP (1) | EP3221304B1 (es) |
| JP (1) | JP6425809B2 (es) |
| KR (1) | KR101903304B1 (es) |
| CN (1) | CN107001319B (es) |
| AR (1) | AR102361A1 (es) |
| AU (1) | AU2015339737B2 (es) |
| BR (1) | BR112017006809B1 (es) |
| CA (1) | CA2963318C (es) |
| CL (1) | CL2017001050A1 (es) |
| EA (1) | EA031504B1 (es) |
| ES (1) | ES2744211T3 (es) |
| MX (1) | MX376894B (es) |
| NZ (1) | NZ730730A (es) |
| TW (1) | TW201627299A (es) |
| WO (1) | WO2016069374A1 (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3581B1 (ar) | 2014-10-29 | 2020-07-05 | Lilly Co Eli | مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي |
| JP7295283B2 (ja) | 2019-06-25 | 2023-06-20 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法 |
| EP4045083B1 (en) | 2019-10-18 | 2024-01-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| NZ786589A (en) | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| US12162872B2 (en) * | 2019-11-27 | 2024-12-10 | Sumitomo Pharma Co., Ltd. | Cycloalkylurea derivative |
| US11352357B2 (en) | 2019-11-27 | 2022-06-07 | Sumitomo Dainippon Pharma Co., Ltd. | Cycloalkylurea derivative |
| CN117736207A (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| TWI832035B (zh) | 2020-02-14 | 2024-02-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| MX2022013619A (es) | 2020-05-01 | 2022-11-16 | Gilead Sciences Inc | Compuestos de 2,4-dioxopirimidina que inhiben cd73. |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| JPWO2023127883A1 (es) | 2021-12-28 | 2023-07-06 | ||
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ｉｋａｒｏｓ鋅指家族降解劑及其用途 |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| PE20250157A1 (es) | 2022-04-21 | 2025-01-22 | Gilead Sciences Inc | Compuestos de modulacion de kras g12d |
| CN119384415A (zh) | 2022-07-01 | 2025-01-28 | 吉利德科学公司 | Cd73化合物 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| KR20250167002A (ko) | 2023-04-11 | 2025-11-28 | 길리애드 사이언시즈, 인코포레이티드 | Kras 조절 화합물 |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6355010B1 (en) | 1999-03-31 | 2002-03-12 | Coaxia, Inc. | Intravascular spinal perfusion and cooling for use during aortic surgery |
| EP2281823A3 (en) | 2003-05-20 | 2011-09-07 | Ajinomoto Co., Inc. | Anti-inflammatory and analgesic piperidine derivatives |
| US20050239921A1 (en) | 2004-04-27 | 2005-10-27 | Birmingham John N | Preparation of organic additive-treated, pyrogenic silica-encapsulated titanium dioxide particles |
| US20080306055A1 (en) * | 2004-12-21 | 2008-12-11 | Astrazeneca Ab | Heterocyclic Mchr1 Antagonists And Their Use In Therapy |
| US8759327B2 (en) * | 2007-04-16 | 2014-06-24 | The Regents Of The University Of Michigan | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism |
| UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| WO2011048004A1 (en) * | 2009-10-23 | 2011-04-28 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin e2 synthase-1 |
| WO2013146970A1 (ja) * | 2012-03-29 | 2013-10-03 | 第一三共株式会社 | 新規キノリン誘導体 |
| US20160122330A1 (en) | 2013-06-20 | 2016-05-05 | Novasaid Ab | Piperidinyl benzoimidazole derivatives as mpge-1 inhibitors |
| JO3581B1 (ar) | 2014-10-29 | 2020-07-05 | Lilly Co Eli | مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي |
-
2015
- 2015-10-19 AR ARP150103381A patent/AR102361A1/es unknown
- 2015-10-19 TW TW104134251A patent/TW201627299A/zh unknown
- 2015-10-22 CN CN201580058924.XA patent/CN107001319B/zh active Active
- 2015-10-22 EP EP15787859.6A patent/EP3221304B1/en active Active
- 2015-10-22 MX MX2017005668A patent/MX376894B/es active IP Right Grant
- 2015-10-22 EA EA201790764A patent/EA031504B1/ru not_active IP Right Cessation
- 2015-10-22 WO PCT/US2015/056955 patent/WO2016069374A1/en not_active Ceased
- 2015-10-22 AU AU2015339737A patent/AU2015339737B2/en active Active
- 2015-10-22 BR BR112017006809-5A patent/BR112017006809B1/pt active IP Right Grant
- 2015-10-22 CA CA2963318A patent/CA2963318C/en active Active
- 2015-10-22 US US15/520,078 patent/US9969714B2/en active Active
- 2015-10-22 JP JP2017522854A patent/JP6425809B2/ja active Active
- 2015-10-22 ES ES15787859T patent/ES2744211T3/es active Active
- 2015-10-22 KR KR1020177011302A patent/KR101903304B1/ko active Active
- 2015-10-22 NZ NZ730730A patent/NZ730730A/en unknown
-
2017
- 2017-04-27 CL CL2017001050A patent/CL2017001050A1/es unknown
-
2018
- 2018-05-08 US US15/974,076 patent/US20180251446A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA201790764A1 (ru) | 2017-08-31 |
| ES2744211T3 (es) | 2020-02-24 |
| EA031504B1 (ru) | 2019-01-31 |
| MX376894B (es) | 2025-03-07 |
| NZ730730A (en) | 2018-08-31 |
| CN107001319A (zh) | 2017-08-01 |
| BR112017006809A2 (pt) | 2017-12-26 |
| BR112017006809B1 (pt) | 2023-02-23 |
| KR101903304B1 (ko) | 2018-10-01 |
| CN107001319B (zh) | 2019-10-01 |
| JP6425809B2 (ja) | 2018-11-21 |
| KR20170063828A (ko) | 2017-06-08 |
| US20180251446A1 (en) | 2018-09-06 |
| WO2016069374A1 (en) | 2016-05-06 |
| JP2018500280A (ja) | 2018-01-11 |
| AU2015339737A1 (en) | 2017-04-20 |
| CA2963318A1 (en) | 2016-05-06 |
| US9969714B2 (en) | 2018-05-15 |
| CL2017001050A1 (es) | 2018-01-12 |
| US20170313679A1 (en) | 2017-11-02 |
| CA2963318C (en) | 2019-06-25 |
| TW201627299A (zh) | 2016-08-01 |
| EP3221304A1 (en) | 2017-09-27 |
| MX2017005668A (es) | 2017-06-26 |
| AU2015339737B2 (en) | 2018-03-15 |
| EP3221304B1 (en) | 2019-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102361A1 (es) | Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| AR102362A1 (es) | Compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| JOP20180113B1 (ar) | مركبات بيريميدين -2-يل امينو -h1- بيرازول كمثبطات lrrk2 للاستخدام في علاج اضطرابات تنكسية عصبية | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| MX375970B (es) | Compuestos de triazolopirimidina y usos de los mismos. | |
| PE20210667A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| AR090292A1 (es) | Compuestos basados en pirazolo[1,5-a]pirimidina, composiciones que los comprenden y metodos que los utilizan | |
| UY33491A (es) | ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?. | |
| CR20150056A (es) | Derivados de azaindol | |
| AR106141A1 (es) | Métodos e intermediarios para la preparación de derivados de ácidos biliares | |
| AR090712A1 (es) | Agentes para tratar trastornos que implican la modulacion de receptores de rianodina | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| UY36651A (es) | Compuestos antiestrogénicos | |
| CU20170007A7 (es) | Compuestos de imidazopiridazina | |
| AR097543A1 (es) | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO | |
| AR097894A1 (es) | Inhibidores terapéuticos de cdk8 o uso de los mismos | |
| AR092971A1 (es) | Inhibidores de agrecanasa | |
| AR097545A1 (es) | COMPUESTOS A BASE DE PIRAZOLO[1,5-a]PIRIMIDINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO | |
| AR095015A1 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| MX2021012248A (es) | Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos. | |
| AR101696A1 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| MX2019012967A (es) | Cristal de base libre de derivados benzofurano y metodo de preparacion. | |
| JO3742B1 (ar) | مركب بيرانو داي بيريدين | |
| EA201591259A1 (ru) | Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |